Dane, F. Et Al. 2015. An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD). ESMO 17th World Congress on Gastrointestinal Cancer , (Barcelona, Spain).

Dane, F., Ozgurdal, K., YALÇIN, S. S., Benekli, M., Aykan, N. F., Yucel, I., ... Ozkan, M.(2015). An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD) . ESMO 17th World Congress on Gastrointestinal Cancer, Barcelona, Spain

Dane, F. Et Al. "An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)," ESMO 17th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 2015

Dane, F. Et Al. "An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)." ESMO 17th World Congress on Gastrointestinal Cancer , Barcelona, Spain, 2015

Dane, F. Et Al. (2015) . "An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)." ESMO 17th World Congress on Gastrointestinal Cancer , Barcelona, Spain.

@conferencepaper{conferencepaper, author={F. Dane Et Al. }, title={An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)}, congress name={ESMO 17th World Congress on Gastrointestinal Cancer}, city={Barcelona}, country={Spain}, year={2015}}